Nothing said here yet.
to join the conversation.
| CARR EDWARDCHIEF ACCOUNTING OFFICER | Sell | 7,928 | $796.2K | Thu, Sep 17 |
| CARR EDWARDCHIEF ACCOUNTING OFFICER | Sell | 6,771 | $686.4K | Thu, Sep 17 |
| CARR EDWARDCHIEF ACCOUNTING OFFICER | Sell | 3,501 | $358.5K | Thu, Sep 17 |
| CARR EDWARDCHIEF ACCOUNTING OFFICER | Sell | 1,100 | $113.5K | Thu, Sep 17 |
| CARR EDWARDCHIEF ACCOUNTING OFFICER | Sell | 700 | $73.1K | Thu, Sep 17 |
| Randhawa SimratEVP, Head of R&D | Sell | 13,309 | $1.4M | Tue, Sep 1 |
| Randhawa SimratEVP, Head of R&D | Sell | 7,215 | $766.6K | Tue, Sep 1 |
| Randhawa SimratEVP, Head of R&D | Sell | 2,600 | $273.5K | Tue, Sep 1 |
| Read SimonDirector | Sell | 2,778 | $326.6K | Wed, Aug 19 |
Dianthus Therapeutics has delivered very strong multi year gains, which naturally raises a question for anyone looking at the stock today.
Dianthus Therapeutics (NASDAQ:DNTH) has earned its first place on Fortune’s Best Workplaces in BioPharma list, highlighting its employee culture as the clinical-stage biotechnology company continues expanding its workforce.
NEW YORK and WALTHAM, Mass., Sept.
Dianthus Therapeutics (DNTH) has moved into the capital markets spotlight after filing a US$500 million follow on equity offering of common stock alongside a broad universal shelf registration.
Dianthus Therapeutics has delivered a very large 3 year return, which puts a lot of focus on whether the current share price still lines up with what its balance sheet actually supports.
On August 4, Dianthus Therapeutics (NASDAQ:DNTH) reported second-quarter 2026 results alongside a stack of pipeline updates that touched nearly every program the company runs.
NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?